Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of cancer"
DOI: 10.1016/j.ejca.2022.03.017
Abstract: BACKGROUND PD-1/PD-L1 inhibitors do not show activity in mismatch repair proficient (MMRp) colorectal cancer. Inhibition of C-C motif chemokine receptor 5 (CCR5) leads to an antitumoral activation of macrophages, affecting immune cell infiltrates. PICCASSO is… read more here.
Keywords: mismatch repair; treatment; cancer; pembrolizumab maraviroc ... See more keywords
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.
Sign Up to like & getrecommendations! Published in 2025 at "Nature"
DOI: 10.1038/s41586-025-09679-4
Abstract: Immune checkpoint blockade has led to paradigm shifts in the treatment of various tumour types1, 2, 3–4, yet limited efficacy has been observed in patients with metastatic mismatch-repair-proficient (pMMR) colorectal cancer5. Here we report clinical… read more here.
Keywords: mismatch; mismatch repair; colon; repair proficient ... See more keywords
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-2474
Abstract: Purpose: Immune checkpoint inhibition (ICI) alone is not active in mismatch repair–proficient (MMR-P) metastatic colorectal cancer (mCRC), nor does radiotherapy alone result in objective systemic benefit. However, combined radiotherapy plus ICI can induce systemic antitumor… read more here.
Keywords: mismatch repair; cancer; study; metastatic colorectal ... See more keywords